经典顺铂类抗肿瘤药物耐药性研究综述  

The Review:Recent Research in Drug Resistance of Classic Cisplatin-Based Drugs

作　　者：高传柱[1] 费凡[1] 王天帅[1] 杨波[1] 杨健[1] 廖霞俐[1] 

机构地区：[1]昆明理工大学生命科学与技术学院,云南昆明650500

出　　处：《昆明理工大学学报（自然科学版）》2013年第6期78-83,共6页Journal of Kunming University of Science and Technology(Natural Science)

基　　金：国家自然科学基金项目(21062009);云南省自然科学基金项目(KKSY201226108);教育部博士点新教师基金项目(20125314120007)资助

摘　　要：作为一类具有独特构效关系的细胞周期非特异性抗肿瘤药物,顺铂在临床治疗卵巢癌、前列腺癌、睾丸癌等实体肿瘤中显示了良好的疗效.然而,经典顺铂类抗肿瘤药物结构上的相似性使得耐药性或交叉耐药性成为限制该类药物临床应用的主要障碍之一.通过对经典铂类抗肿瘤药物耐药机制的研究和探讨,不仅可以指导已上市铂类药物的临床使用,而且能够有效地针对其耐药机制的产生来进行更为合理的药物设计和结构修饰改造,从而获得具有更好疗效、更低毒副作用的新型铂类抗肿瘤药物.As a class of cell cycle non - specific anticancer drugs with a unique structure - activity, Cisplatin shows good efficacy in the clinical treatment of ovarian cancer, prostate cancer, testicular cancer and other solid tumors. However, resistance or cross - resistance of the eisplatin analogous is becoming one of the main obstacles for cisplatin and its analogous, which limits their clinical applications. Understanding the resistance mechanisms of the classic platinum - based anticancer drugs not only helps doctors in clinical applications, but also gives us more targeted information in rational drug design to obtain novel platinum -based drugs with better efficacy and lower toxicity. This paper reviews research progress of the classic cisplatin analgous for their drug resistance mechanisms.

关 键 词：顺铂 抗肿瘤药物 耐药机制 研究进展 

分 类 号：R730.35[医药卫生—肿瘤]